Skip to main content
Erschienen in: European Radiology 10/2015

01.10.2015 | Hepatobiliary-Pancreas

Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout?

verfasst von: Ijin Joo, Jeong Min Lee, Dong Ho Lee, Ju Hyeon Jeon, Joon Koo Han, Byung Ihn Choi

Erschienen in: European Radiology | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To determine which dynamic phase(s) of gadoxetic acid-enhanced MRI is most appropriate to assess “washout” in the noninvasive diagnosis of hepatocellular carcinoma (HCC) based on hemodynamic pattern.

Methods

In this retrospective cohort study, 288 consecutive patients with chronic liver disease presented with 387 arterially enhancing nodules (292 HCCs, 95 non-HCCs) (≥1 cm) on gadoxetic acid-enhanced MRI. All HCCs were confirmed by histopathology or by their typical enhancement pattern on dynamic liver CT. MR imaging diagnosis of HCC was made using criteria of arterial enhancement and hypointensity relative to the surrounding parenchyma (1) on the portal-venous phase (PVP), (2) on the PVP and/or transitional phase (TP), or (3) on the PVP and/or TP, and/or hepatobiliary phase (HBP).

Results

For the noninvasive diagnosis of HCC, criterion 1 provided significantly higher specificity (97.9 %; 95 % confidence interval, 92.6 – 99.7 %) than criteria 2 (86.3 %; 77.7 – 92.5 %), or 3 (48.4 %; 38.0 – 58.9 %). Conversely, higher sensitivity was obtained with criterion 3 (93.8 %; 90.4 – 96.3 %) than with criterion 2 (86.6 %; 82.2 – 90.3 %) or 1 (70.9 %; 65.3 – 76.0 %).

Conclusions

To make a sufficiently specific diagnosis of HCC using gadoxetic acid-enhanced MRI based on typical enhancement features, washout should be determined on the PVP alone rather than combined with hypointensity on the TP or HBP.

Key points

Gadoxetic acid-enhanced MRI enhancement features can be used to diagnose HCC.
Washout should be determined on the PVP alone for high specificity.
Hypointensity on the TP or HBP increases sensitivity but lowers specificity.
Literatur
1.
Zurück zum Zitat Tang A, Cruite I, Sirlin CB (2013) Toward a standardized system for hepatocellular carcinoma diagnosis using computed tomography and MRI. Expert Rev Gastroenterol Hepatol 7:269–279CrossRefPubMed Tang A, Cruite I, Sirlin CB (2013) Toward a standardized system for hepatocellular carcinoma diagnosis using computed tomography and MRI. Expert Rev Gastroenterol Hepatol 7:269–279CrossRefPubMed
3.
Zurück zum Zitat Bota S, Piscaglia F, Marinelli S, Pecorelli A, Terzi E, Bolondi L (2012) Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma. Liver Cancer 1:190–200PubMedCentralCrossRefPubMed Bota S, Piscaglia F, Marinelli S, Pecorelli A, Terzi E, Bolondi L (2012) Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma. Liver Cancer 1:190–200PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943 European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943
5.
6.
Zurück zum Zitat Kim SH, Lee J, Kim MJ et al (2009) Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 192:1675–1681CrossRefPubMed Kim SH, Lee J, Kim MJ et al (2009) Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 192:1675–1681CrossRefPubMed
7.
Zurück zum Zitat Inoue T, Kudo M, Komuta M et al (2012) Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol 47:1036–1047CrossRefPubMed Inoue T, Kudo M, Komuta M et al (2012) Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol 47:1036–1047CrossRefPubMed
8.
Zurück zum Zitat Park G, Kim YK, Kim CS, Yu HC, Hwang SB (2010) Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol 83:1010–1016PubMedCentralCrossRefPubMed Park G, Kim YK, Kim CS, Yu HC, Hwang SB (2010) Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol 83:1010–1016PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Sano K, Ichikawa T, Motosugi U et al (2011) Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 261:834–844CrossRefPubMed Sano K, Ichikawa T, Motosugi U et al (2011) Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 261:834–844CrossRefPubMed
10.
Zurück zum Zitat Kudo M (2010) Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma? Oncology 78(Suppl 1):87–93CrossRefPubMed Kudo M (2010) Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma? Oncology 78(Suppl 1):87–93CrossRefPubMed
11.
Zurück zum Zitat Kudo M, Izumi N, Kokudo N et al (2011) Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 29:339–364CrossRefPubMed Kudo M, Izumi N, Kokudo N et al (2011) Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 29:339–364CrossRefPubMed
12.
Zurück zum Zitat Bashir MR, Gupta RT, Davenport MS et al (2013) Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis? J Magn Reson Imaging 37:398–406CrossRefPubMed Bashir MR, Gupta RT, Davenport MS et al (2013) Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis? J Magn Reson Imaging 37:398–406CrossRefPubMed
13.
Zurück zum Zitat Palmucci S (2014) Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI. World J Hepatol 6:477–485PubMedCentralCrossRefPubMed Palmucci S (2014) Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI. World J Hepatol 6:477–485PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Lee JM, Zech CJ, Bolondi L et al (2011) Consensus report of the 4th International Forum for Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid Magnetic Resonance Imaging. Korean J Radiol 12:403–415PubMedCentralCrossRefPubMed Lee JM, Zech CJ, Bolondi L et al (2011) Consensus report of the 4th International Forum for Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid Magnetic Resonance Imaging. Korean J Radiol 12:403–415PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Sun HY, Lee JM, Shin CI et al (2010) Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Investig Radiol 45:96–103CrossRef Sun HY, Lee JM, Shin CI et al (2010) Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Investig Radiol 45:96–103CrossRef
16.
Zurück zum Zitat Motosugi U, Ichikawa T, Sou H et al (2010) Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 256:151–158CrossRefPubMed Motosugi U, Ichikawa T, Sou H et al (2010) Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 256:151–158CrossRefPubMed
17.
Zurück zum Zitat Kudo M (2011) Diagnostic imaging of hepatocellular carcinoma: recent progress. Oncology 81(Suppl 1):73–85CrossRefPubMed Kudo M (2011) Diagnostic imaging of hepatocellular carcinoma: recent progress. Oncology 81(Suppl 1):73–85CrossRefPubMed
18.
Zurück zum Zitat Tateyama A, Fukukura Y, Takumi K et al (2012) Gd-EOB-DTPA-enhanced magnetic resonance imaging features of hepatic hemangioma compared with enhanced computed tomography. World J Gastroenterol 18:6269–6276PubMedCentralCrossRefPubMed Tateyama A, Fukukura Y, Takumi K et al (2012) Gd-EOB-DTPA-enhanced magnetic resonance imaging features of hepatic hemangioma compared with enhanced computed tomography. World J Gastroenterol 18:6269–6276PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Doo KW, Lee CH, Choi JW, Lee J, Kim KA, Park CM (2009) “Pseudo washout” sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor. AJR Am J Roentgenol 193:W490–W496CrossRefPubMed Doo KW, Lee CH, Choi JW, Lee J, Kim KA, Park CM (2009) “Pseudo washout” sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor. AJR Am J Roentgenol 193:W490–W496CrossRefPubMed
20.
Zurück zum Zitat Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW (2014) Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol 109:1223–1233CrossRefPubMed Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW (2014) Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol 109:1223–1233CrossRefPubMed
21.
Zurück zum Zitat An C, Park MS, Kim D et al (2013) Added value of subtraction imaging in detecting arterial enhancement in small (<3 cm) hepatic nodules on dynamic contrast-enhanced MRI in patients at high risk of hepatocellular carcinoma. Eur Radiol 23:924–930CrossRefPubMed An C, Park MS, Kim D et al (2013) Added value of subtraction imaging in detecting arterial enhancement in small (<3 cm) hepatic nodules on dynamic contrast-enhanced MRI in patients at high risk of hepatocellular carcinoma. Eur Radiol 23:924–930CrossRefPubMed
22.
Zurück zum Zitat Nino-Murcia M, Olcott EW, Jeffrey RB Jr, Lamm RL, Beaulieu CF, Jain KA (2000) Focal liver lesions: pattern-based classification scheme for enhancement at arterial phase CT. Radiology 215:746–751CrossRefPubMed Nino-Murcia M, Olcott EW, Jeffrey RB Jr, Lamm RL, Beaulieu CF, Jain KA (2000) Focal liver lesions: pattern-based classification scheme for enhancement at arterial phase CT. Radiology 215:746–751CrossRefPubMed
23.
Zurück zum Zitat Jelic S, Sotiropoulos GC (2010) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v59–v64CrossRefPubMed Jelic S, Sotiropoulos GC (2010) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v59–v64CrossRefPubMed
24.
Zurück zum Zitat Oto A, Kulkarni K, Nishikawa R, Baron RL (2010) Contrast enhancement of hepatic hemangiomas on multiphase MDCT: Can we diagnose hepatic hemangiomas by comparing enhancement with blood pool? AJR Am J Roentgenol 195:381–386CrossRefPubMed Oto A, Kulkarni K, Nishikawa R, Baron RL (2010) Contrast enhancement of hepatic hemangiomas on multiphase MDCT: Can we diagnose hepatic hemangiomas by comparing enhancement with blood pool? AJR Am J Roentgenol 195:381–386CrossRefPubMed
25.
Zurück zum Zitat Vilanova JC, Barcelo J, Smirniotopoulos JG et al (2004) Hemangioma from head to toe: MR imaging with pathologic correlation. Radiographics 24:367–385CrossRefPubMed Vilanova JC, Barcelo J, Smirniotopoulos JG et al (2004) Hemangioma from head to toe: MR imaging with pathologic correlation. Radiographics 24:367–385CrossRefPubMed
26.
Zurück zum Zitat Ahn JH, Yu JS, Hwang SH, Chung JJ, Kim JH, Kim KW (2010) Nontumorous arterioportal shunts in the liver: CT and MRI findings considering mechanisms and fate. Eur Radiol 20:385–394CrossRefPubMed Ahn JH, Yu JS, Hwang SH, Chung JJ, Kim JH, Kim KW (2010) Nontumorous arterioportal shunts in the liver: CT and MRI findings considering mechanisms and fate. Eur Radiol 20:385–394CrossRefPubMed
27.
Zurück zum Zitat Gabata T, Kadoya M, Matsui O et al (2001) Dynamic CT of hepatic abscesses: significance of transient segmental enhancement. AJR Am J Roentgenol 176:675–679CrossRefPubMed Gabata T, Kadoya M, Matsui O et al (2001) Dynamic CT of hepatic abscesses: significance of transient segmental enhancement. AJR Am J Roentgenol 176:675–679CrossRefPubMed
28.
Zurück zum Zitat Byun JH, Yang DH, Yoon SE et al (2006) Contrast-enhancing hepatic eosinophilic abscess during the hepatic arterial phase: a mimic of hepatocellular carcinoma. AJR Am J Roentgenol 186:168–173CrossRefPubMed Byun JH, Yang DH, Yoon SE et al (2006) Contrast-enhancing hepatic eosinophilic abscess during the hepatic arterial phase: a mimic of hepatocellular carcinoma. AJR Am J Roentgenol 186:168–173CrossRefPubMed
29.
Zurück zum Zitat Grieser C, Steffen IG, Seehofer D et al (2013) Histopathologically confirmed focal nodular hyperplasia of the liver: gadoxetic acid-enhanced MRI characteristics. Magn Reson Imaging 31:755–760CrossRefPubMed Grieser C, Steffen IG, Seehofer D et al (2013) Histopathologically confirmed focal nodular hyperplasia of the liver: gadoxetic acid-enhanced MRI characteristics. Magn Reson Imaging 31:755–760CrossRefPubMed
30.
Zurück zum Zitat Yoon SH, Lee JM, So YH et al (2009) Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter: tumor size and cellular differentiation. AJR Am J Roentgenol 193:W482–W489CrossRefPubMed Yoon SH, Lee JM, So YH et al (2009) Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter: tumor size and cellular differentiation. AJR Am J Roentgenol 193:W482–W489CrossRefPubMed
31.
Zurück zum Zitat Forner A, Vilana R, Ayuso C et al (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47:97–104CrossRefPubMed Forner A, Vilana R, Ayuso C et al (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47:97–104CrossRefPubMed
32.
Zurück zum Zitat Hayashi PH, Trotter JF, Forman L et al (2004) Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD. Liver Transpl 10:42–48CrossRefPubMed Hayashi PH, Trotter JF, Forman L et al (2004) Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD. Liver Transpl 10:42–48CrossRefPubMed
33.
Zurück zum Zitat Barreiros AP, Piscaglia F, Dietrich CF (2012) Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): comments on AASLD guidelines. J Hepatol 57:930–932CrossRefPubMed Barreiros AP, Piscaglia F, Dietrich CF (2012) Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): comments on AASLD guidelines. J Hepatol 57:930–932CrossRefPubMed
34.
Zurück zum Zitat Sangiovanni A, Manini MA, Iavarone M et al (2010) The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 59:638–644CrossRefPubMed Sangiovanni A, Manini MA, Iavarone M et al (2010) The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 59:638–644CrossRefPubMed
35.
Zurück zum Zitat El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752–1763CrossRefPubMed El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752–1763CrossRefPubMed
36.
Zurück zum Zitat Liu YI, Kamaya A, Jeffrey RB, Shin LK (2012) Multidetector computed tomography triphasic evaluation of the liver before transplantation: importance of equilibrium phase washout and morphology for characterizing hypervascular lesions. J Comput Assist Tomogr 36:213–219CrossRefPubMed Liu YI, Kamaya A, Jeffrey RB, Shin LK (2012) Multidetector computed tomography triphasic evaluation of the liver before transplantation: importance of equilibrium phase washout and morphology for characterizing hypervascular lesions. J Comput Assist Tomogr 36:213–219CrossRefPubMed
37.
Zurück zum Zitat Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS (2005) Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 11:281–289CrossRefPubMed Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS (2005) Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 11:281–289CrossRefPubMed
38.
Zurück zum Zitat Cereser L, Furlan A, Bagatto D et al (2010) Comparison of portal venous and delayed phases of gadolinium-enhanced magnetic resonance imaging study of cirrhotic liver for the detection of contrast washout of hypervascular hepatocellular carcinoma. J Comput Assist Tomogr 34:706–711CrossRefPubMed Cereser L, Furlan A, Bagatto D et al (2010) Comparison of portal venous and delayed phases of gadolinium-enhanced magnetic resonance imaging study of cirrhotic liver for the detection of contrast washout of hypervascular hepatocellular carcinoma. J Comput Assist Tomogr 34:706–711CrossRefPubMed
39.
Zurück zum Zitat Burkholz KJ, Silva AC (2008) AJR teaching file: hypervascular metastasis or hepatic hemangioma? AJR Am J Roentgenol 190:S53–S56CrossRefPubMed Burkholz KJ, Silva AC (2008) AJR teaching file: hypervascular metastasis or hepatic hemangioma? AJR Am J Roentgenol 190:S53–S56CrossRefPubMed
40.
Zurück zum Zitat Ringe KI, Husarik DB, Sirlin CB, Merkle EM (2010) Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 195:13–28CrossRefPubMed Ringe KI, Husarik DB, Sirlin CB, Merkle EM (2010) Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 195:13–28CrossRefPubMed
41.
Zurück zum Zitat Quaia E, Pizzolato R, De Paoli L, Angileri R, Ukmar M, Cova MA (2013) Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging. J Magn Reson Imaging 37:892–902CrossRefPubMed Quaia E, Pizzolato R, De Paoli L, Angileri R, Ukmar M, Cova MA (2013) Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging. J Magn Reson Imaging 37:892–902CrossRefPubMed
42.
Zurück zum Zitat Xu J, Igarashi S, Sasaki M et al (2012) Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers. Liver Int 32:1156–1164CrossRefPubMed Xu J, Igarashi S, Sasaki M et al (2012) Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers. Liver Int 32:1156–1164CrossRefPubMed
43.
Zurück zum Zitat Rimola J, Forner A, Reig M et al (2009) Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 50:791–798CrossRefPubMed Rimola J, Forner A, Reig M et al (2009) Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 50:791–798CrossRefPubMed
44.
Zurück zum Zitat Peporte AR, Sommer WH, Nikolaou K, Reiser MF, Zech CJ (2013) Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 82:e101–e106CrossRefPubMed Peporte AR, Sommer WH, Nikolaou K, Reiser MF, Zech CJ (2013) Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 82:e101–e106CrossRefPubMed
45.
Zurück zum Zitat Chung YE, Park MS, Park YN et al (2009) Hepatocellular carcinoma variants: radiologic-pathologic correlation. AJR Am J Roentgenol 193:W7–W13CrossRefPubMed Chung YE, Park MS, Park YN et al (2009) Hepatocellular carcinoma variants: radiologic-pathologic correlation. AJR Am J Roentgenol 193:W7–W13CrossRefPubMed
46.
Zurück zum Zitat Fukukura Y, Taguchi J, Nakashima O, Wada Y, Kojiro M (1997) Combined hepatocellular and cholangiocarcinoma: correlation between CT findings and clinicopathological features. J Comput Assist Tomogr 21:52–58CrossRefPubMed Fukukura Y, Taguchi J, Nakashima O, Wada Y, Kojiro M (1997) Combined hepatocellular and cholangiocarcinoma: correlation between CT findings and clinicopathological features. J Comput Assist Tomogr 21:52–58CrossRefPubMed
47.
Zurück zum Zitat Fowler KJ, Sheybani A, Parker RA 3rd et al (2013) Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol 201:332–339CrossRefPubMed Fowler KJ, Sheybani A, Parker RA 3rd et al (2013) Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol 201:332–339CrossRefPubMed
48.
Zurück zum Zitat Sanada Y, Shiozaki S, Aoki H, Takakura N, Yoshida K, Yamaguchi Y (2005) A clinical study of 11 cases of combined hepatocellular-cholangiocarcinoma Assessment of enhancement patterns on dynamics computed tomography before resection. Hepatol Res 32:185–195CrossRefPubMed Sanada Y, Shiozaki S, Aoki H, Takakura N, Yoshida K, Yamaguchi Y (2005) A clinical study of 11 cases of combined hepatocellular-cholangiocarcinoma Assessment of enhancement patterns on dynamics computed tomography before resection. Hepatol Res 32:185–195CrossRefPubMed
49.
Zurück zum Zitat Teefey SA, Hildeboldt CC, Dehdashti F et al (2003) Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 226:533–542CrossRefPubMed Teefey SA, Hildeboldt CC, Dehdashti F et al (2003) Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 226:533–542CrossRefPubMed
50.
Zurück zum Zitat Lee WS, Lee KW, Heo JS et al (2006) Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today 36:892–897CrossRefPubMed Lee WS, Lee KW, Heo JS et al (2006) Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today 36:892–897CrossRefPubMed
Metadaten
Titel
Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout?
verfasst von
Ijin Joo
Jeong Min Lee
Dong Ho Lee
Ju Hyeon Jeon
Joon Koo Han
Byung Ihn Choi
Publikationsdatum
01.10.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 10/2015
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-015-3686-3

Weitere Artikel der Ausgabe 10/2015

European Radiology 10/2015 Zur Ausgabe

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.